Trinity College Dublin


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Dr. Sharon O'Toole

Snr Experimental Officer (Obstetrics)
TRINITY CENTRE, S J H

Senior Research Fellow (Histopathology)


Sharon O'Toole obtained a BSc Hons in UCG in 1994 and received an award for outstanding results. She went on to receive one of the limited places on the MSc Biotechnology course and graduated in 1996. From there she worked as a QC analyst in Schering Plough. She was then selected to assist one of the leading members of the technical transfer team who was involved in the transfer of technology from the US. An opportunity then arose in TCD, which would eventually lead to a PhD. She received the O'Meara scholarship from Trinity. She has gained enormous experience in the area of ovarian cancer and has played a major role in the development of studies in gynaecological cancer. During the course of her PhD she showed innovative skills in developing assay systems for chemosensitivity/resistance testing. Sharon forged many links with industry and became principal investigator on a study funded by Bristol Myers Squibb. She has worked directly with Applied Biosystems and presented for them at symposiums. Other funding she received for studies included the royal city of Dublin hospital trust fund and the HRB. She then became a coinvestigator on a 5th framework study funded by the European commission with a consortium of eight centres throughout Europe. She has presented at both national and international conferences and published in peer-reviewed journals. She was nominated to present at the Blair Bell symposium in London. She received an award from the International society for preventive oncology for her presentation in Geneva
  Gynaecology oncology   Obstetrics/Gynecology   Oestregens in age related urogenital diseases
 Identification of novel biomarkers in recurrent/chemoresistant ovarian cancer
 A Consortium of researchers dedicated to understanding and treatment of ovarian cancer: The DISCOVARY Consortium
 Ageing and the Urogenital Tract
 Chemosensitivity testing in gynaecological cancers

Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
French Fluent Medium Medium
Details Date From Date To
Member of European Association for Cancer Research. Member of Irish Association for Cancer Research
Non-invasive early markers in Ovarian Cancer. Non-invasive early molecular markers in cancer in, editor(s)Debmalya Barh, Angelo Carpi, Mukesh Verma, and Mehmet Gunduz , Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis, Taylor and Francis, 2013, [O'Toole S, Ankuta E, Langhe R, Cahill DJ, Murphy MA, Martin C, McEvoy L, Spillane C, Sheils O, Petricoin C, Liotta L, O'Leary JJ.], Book Chapter, PUBLISHED
Laios A, Mohamed BM, Kelly L, Flavin R, Finn S, McEvoy L, Gallagher M, Martin C, Sheils O, Ring M, Davies A, Lawson M, Gleeson N, D'Arcy T, d'Adhemar C, Norris L, Langhe R, Saadeh FA, O'Leary JJ, O'Toole SA, Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening., International journal of molecular sciences, 14, (1), 2013, p2085-103 , Journal Article, PUBLISHED  TARA - Full Text
Abu Saadeh F, Norris L, O'Toole S, Gleeson N, Venous thromboembolism in ovarian cancer: Incidence, risk factors and impact on survival., European Journal of Obstetrics & Gynecology and Reproductive Biology , 170, (1), 2013, p214 - 218, Journal Article, PUBLISHED  Other
Abu Saadeh, Norris L, O'Toole S, Mohamed BM, Langhe R, O'Leary J, Gleeson N, Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk., Thrombosis Research, 132, 2013, p627 - 634, Journal Article, PUBLISHED  DOI
Murphy MA, O'Connell DJ, O'Kane SL, O'Brien JK, O'Toole S, Martin C, Sheils O, O'Leary JJ, Cahill DJ, Epitope presentation is an important determinant of the utility of antigens identified from protein arrays in the development of autoantibody diagnostic assays, Journal of Proteomics, 75, (15), 2012, p4668 - 4675, Notes: [. ], Journal Article, PUBLISHED  TARA - Full Text
Gallagher MF, Heffron CC, Laios A, O'Toole SA, Ffrench B, Smyth PC, Flavin RJ, Elbaruni SA, Spillane CD, Martin CM, Shelis OM, O'Leary JJ. , Suppression of Cancer Stemness p21-regulating mRNA and microRNA Signatures in Recurrent Ovarian Cancer Patient Samples. , Journal of Ovarian Research, 5, (1), 2012, p2-, Journal Article, PUBLISHED  DOI
Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A, Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer., The Journal of pathology, 226, (5), 2012, p746-55 , Journal Article, PUBLISHED
Karl Egan., Darragh Crowley., Paul Smyth, Sharon O'Toole, Cathy Spillane, Cara Martin, Michael Gallagher, Aoife Canney, Lucy Norris, Niamh Conlon, Lynda McEvoy2, Brendan Ffrench2, Britta Stordal, Helen Keegan, Stephen Finn, Victoria McEneaney, Alex Laios, Jens Ducre, Eimear Dunne, Leila Smith, Michael Berndt, Orla Sheils, Dermot Kenny, John O'Leary, Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer Cells, PLoS ONE, 6, (10, e26125), 2011, Journal Article, PUBLISHED  TARA - Full Text
Ovarian Cancer Chemoresistance in, editor(s)Dr. rer. nat. Manfred Schwab , Encyclopedia of Cancer, SpringerReference, 2010, [O'Toole SA, O'Leary JJ], Book Chapter, PUBLISHED  URL
Gene expression profiling in cervical cancer: identification of novel markers for disease diagnosis and therapy in, Methods Mol Biol, 2009, pp333 - 359, [Martin CM, Astbury K, McEvoy L, O'Toole S, Sheils O, O'Leary JJ], Book Chapter, PUBLISHED  DOI
  

Page 1 of 3
Laios A, O'Toole SA, Sheppard BL, Gleeson NC, D'Arcy T, McGuinness EPJ, Ring M, Sheils O, O'Leary JJ. (ed.), Irish Association for Cancer Research, Galway, Ireland, March 2006, 2006, Proceedings of a Conference, PRESENTED
O'Toole SA, Sheppard BL, McGuinness EPJ, Gleeson NC, Bonnar J, Predicting the response of gynaecological tumours to chemotherapy. , Anticancer Research , 24, (2A), 2004, p533 - 534, Journal Article, PUBLISHED
O'Toole SA, Sheppard BL, McGuinness EPJ, Gleeson NC, Yoneda M, Bonnar J., Determining the response of gynaecological tumours to chemotherapy using an MTS cytotoxicity assay in combination with an explant culture technique, British Journal of Cancer , 86, (Suppl 1), 2002, pS46 - S46, Journal Article, PUBLISHED
O'Toole S, Sheppard B.L., Bonnar J, McGuinness E, Gleeson N, Cell Culture drug sensitivity/resistance testing of malignant gynaecological tumours. , British Journal of Obstetrics and Gynaecology , 107, (6), 2000, p818 - 819, Journal Article, PUBLISHED

  

-Early diagnostics in ovarian cancer -Chemoresistance in ovarian cancer Chemosensitivity/Resistance testing of malignant gynaecological tumours -Examination of Fibrinolytic systems of malignant gynaecological tumours -Examination of angiogenesis in ovarian cancers. -Examination of multidrug resistance genes in gynaecological tumours. -Estrogen regulated genes in endometrial cancer. -PhytoSERMs and Endometrial Cancer